Akkoyunlu Muhammed Emin, Ilhan Mahmut Muzaffer, Bayram Mehmet, Taşan Ertuğrul, Yakar Fatih, Ozçelik Hatice Kutbay, Karakose Fatmanur, Kart Levent
Department of Pulmonology, Bezmialem Vakif University Medical School, Istanbul, Turkey.
Respir Med. 2013 Nov;107(11):1803-9. doi: 10.1016/j.rmed.2013.08.043. Epub 2013 Sep 11.
Acromegaly is a disease in which uncontrolled release of growth hormone occurs after closure of epiphyseal plates, causing changes in the body that can lead to sleep disordered breathing (SDB). No definite guidelines regarding the treatment of SDB in acromegaly are available. In this study, we aimed to investigate the prevalence of SDB in acromegaly and whether hormonal control alters the necessity of positive airway pressure (PAP) therapy in acromegaly patients with SDB.
Forty-two acromegaly patients were included in the study and divided into two groups according to disease status, i.e., active or well controlled. All patients underwent polysomnography. Fourteen patients with active acromegaly were diagnosed with SDB and were evaluated for PAP therapy with polysomnography both before and 6 months after disease control was achieved.
Sleep-disorder breathing was diagnosed in 22 of 42 patients, 7 of 20 patients with controlled-disease and 15 of 20 patients with active diseases. There were significant reductions in respiratory disturbance index (RDI), apnea index, desaturation index, central apnea number, and rapid eye movement-phase RDI at the control polysomnography. Initially, PAP therapy was indicated in 12 of 14 patients and PAP therapy indication held in 11 patients after acromegaly control was achieved.
Our study revealed that over half of patients with acromegaly had SDB. Furthermore, SDB severity decreases with acromegaly treatment; however, this decrease does not change the indication for PAP therapy; therefore, PAP therapy should not be delayed in acromegalic SDB patients.
肢端肥大症是一种在骨骺板闭合后生长激素不受控制地释放的疾病,会导致身体发生变化,进而引发睡眠呼吸障碍(SDB)。目前尚无关于肢端肥大症患者睡眠呼吸障碍治疗的明确指南。在本研究中,我们旨在调查肢端肥大症患者睡眠呼吸障碍的患病率,以及激素控制是否会改变肢端肥大症合并睡眠呼吸障碍患者使用气道正压通气(PAP)治疗的必要性。
42例肢端肥大症患者纳入本研究,并根据疾病状态分为两组,即活动期或病情得到良好控制组。所有患者均接受多导睡眠监测。14例活动期肢端肥大症患者被诊断为睡眠呼吸障碍,并在疾病得到控制前及控制后6个月接受多导睡眠监测评估PAP治疗。
42例患者中有22例被诊断为睡眠呼吸障碍,其中病情得到控制的20例患者中有7例,活动期疾病的20例患者中有15例。在对照多导睡眠监测中,呼吸紊乱指数(RDI)、呼吸暂停指数、血氧饱和度下降指数、中枢性呼吸暂停次数和快速眼动期RDI均有显著降低。最初,14例患者中有12例需要PAP治疗,在肢端肥大症得到控制后,11例患者仍需PAP治疗。
我们的研究表明,超过一半的肢端肥大症患者患有睡眠呼吸障碍。此外,睡眠呼吸障碍的严重程度随肢端肥大症治疗而降低;然而,这种降低并未改变PAP治疗的指征;因此,肢端肥大症合并睡眠呼吸障碍患者不应延迟PAP治疗。